Clinical trial registry record

SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 18, 2011.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00331864
Last registry update
February 18, 2011
Status
Completed
Phase
Phase 3
Sponsor
Novartis
Enrollment
531
Countries
Switzerland
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
531
Population
ALL · 50 Years
Duration
2006-04-01 to 2008-04-01
Intervention
Ranibizumab
Comparator
Not reported
Outcomes measured
Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — Baseline through end of study (12 month trea…; Percentage of Patients With Targeted Grade 3 Adverse Events (AEs) in the Study Eye — Baseline through end of study (12…; Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 3 — Baseline and Month 3; Mean Change in Best Corrected Visual Acuity (BCVA) of the Study Eye From Baseline to Month 12 — Baseline and Month 12; Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 3 — Baseline and Month 3; Mean Change in Central Retinal Thickness of the Study Eye From Baseline to Month 12 — Baseline and Month 12; Time to the First Retreatment After Month 2 — Month 2 to Month 11; Total Number of Treatments — Baseline (Month 0) to Month 11
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON